moa of glp-1 agonists Evolution GLP‐1 Receptor for Diabetes Treatment Frontiers | Mechanisms of action

Phase 2 orforglipron data demonstrated 14.7% body weight reduction at 45mg without food or water requirements, and the addressable patient expansion is estimated to grow the anti-obesity medication market by 180 million new prescription patients between 2027 and 2032

Charge-offs rose modestly on a sequential basis but largely followed seasonal patterns, while delinquency rates moved lower

10.1038/s41575-021-00440-6 31 Sanchez-RodriguezE.Egea-ZorrillaA.Plaza-DiazJ.Aragon-VelaJ.Munoz-QuezadaS.Tercedor-SanchezL.et al (2020)

By modulating NNMT, 5-Amino-1MQ may enhance NAD availability , promote lean body composition , and support healthy aging and mitochondrial function